La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Novoray Bilan de santé

Santé financière contrôle des critères 6/6

Novoray possède un total de capitaux propres de CN¥1.4B et une dette totale de CN¥89.3M, ce qui porte son ratio d'endettement à 6.4%. Son actif total et son passif total sont CN¥1.8B et de CN¥389.1M. L'EBIT de Novoray est CN¥192.2M ce qui fait que son ratio de couverture des intérêts -13.1. Elle dispose de liquidités et de placements à court terme de CN¥378.9M.

Informations clés

6.4%

Ratio d'endettement

CN¥89.27m

Dette

Ratio de couverture des intérêts	-13.1x
Argent liquide	CN¥378.87m
Fonds propres	CN¥1.40b
Total du passif	CN¥389.08m
Total des actifs	CN¥1.79b

Mises à jour récentes de la santé financière

Does Novoray (SHSE:688300) Have A Healthy Balance Sheet?

Apr 23

Recent updates

If EPS Growth Is Important To You, Novoray (SHSE:688300) Presents An Opportunity

Aug 20

If EPS Growth Is Important To You, Novoray (SHSE:688300) Presents An Opportunity

May 13

Does Novoray (SHSE:688300) Have A Healthy Balance Sheet?

Apr 23

Novoray's (SHSE:688300) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 01

Earnings Miss: Novoray Corporation Missed EPS By 8.5% And Analysts Are Revising Their Forecasts

Mar 28

Subdued Growth No Barrier To Novoray Corporation (SHSE:688300) With Shares Advancing 28%

Mar 01

When Should You Buy Novoray Corporation (SHSE:688300)?

Feb 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 688300 ( CN¥977.3M ) dépassent ses passifs à court terme ( CN¥236.0M ).

Passif à long terme: Les actifs à court terme de 688300 ( CN¥977.3M ) dépassent ses passifs à long terme ( CN¥153.1M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 688300 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 688300 a été réduit de 8.7% à 6.4% au cours des 5 dernières années.

Couverture de la dette: La dette de 688300 est bien couverte par le flux de trésorerie opérationnel ( 211.7% ).

Couverture des intérêts: 688300 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Novoray Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Does Novoray (SHSE:688300) Have A Healthy Balance Sheet?

Recent updates

If EPS Growth Is Important To You, Novoray (SHSE:688300) Presents An Opportunity

Novoray's (SHSE:688300) Returns On Capital Not Reflecting Well On The Business

Price target increased by 18% to CN¥65.00

What Novoray Corporation's (SHSE:688300) P/E Is Not Telling You

Novoray Corporation to Report First Half, 2024 Results on Aug 26, 2024

Why Novoray Corporation (SHSE:688300) Could Be Worth Watching

Dividend of CN¥0.50 announced

If EPS Growth Is Important To You, Novoray (SHSE:688300) Presents An Opportunity

First quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.15 in 1Q 2023)

Does Novoray (SHSE:688300) Have A Healthy Balance Sheet?

Novoray's (SHSE:688300) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Novoray Corporation to Report Q1, 2024 Results on Apr 26, 2024

Earnings Miss: Novoray Corporation Missed EPS By 8.5% And Analysts Are Revising Their Forecasts

Novoray Corporation, Annual General Meeting, Apr 19, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Subdued Growth No Barrier To Novoray Corporation (SHSE:688300) With Shares Advancing 28%

When Should You Buy Novoray Corporation (SHSE:688300)?

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.21 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.26 in 2Q 2022)

Now 21% undervalued

Investor sentiment improves as stock rises 15%

First quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.34 in 1Q 2022)

Investor sentiment improves as stock rises 32%

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: CN¥1.51 (vs CN¥1.39 in FY 2021)

Price target decreased to CN¥54.21

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.58 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.57 (vs CN¥0.49 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target increased to CN¥118

Less than half of directors are independent

Full year 2021 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.33 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.29 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target increased to CN¥69.68

First quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.21 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥40.31

New 90-day low: CN¥40.48

New 90-day low: CN¥47.02

Market pulls back on stock over the past week

New 90-day low: CN¥50.10

Third quarter earnings released

Analysts lower revenue estimates to CN¥394.0m

Novoray Corporation to Report Q3, 2020 Results on Oct 22, 2020

New 90-day low: CN¥51.88

New 90-day low - CN¥53.99

First half earnings released

Novoray Corporation to Report First Half, 2020 Results on Aug 26, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines